GNPXGenprex Inc
$7.70
$0.305
(3.81%)
Pre-Market
Reported EarningsAug 28
Mkt Cap$3.64M
Vol428.00
Genprex Receives a Notice of Allowance from The Canadian Intellectual Property Office for a Patent Claiming the Combination of Reqorsa Gene Therapy with Either PD-1 or PD-L1 Antibodies to Treat Cancer
Genprex Receives a Notice of Allowance from The Canadian Intellectual Property Office for a Patent Claiming the Combination of Reqorsa Gene Therapy with Either PD-1 or PD-L1 Antibodies to Treat Cancer Genprex Receives a Notice of Allowance from The Canadian Intellectual Property Office for a Patent...
PR Newswire
Genprex to Participate at BIO International Convention 2026
Genprex to Participate at BIO International Convention 2026 Genprex to Participate at BIO International Convention 2026 PR Newswire AUSTIN, Texas, June 17, 2026 The BIO International Convention Brings Together More Than 20,000 Biotech Industry Leaders From Around The WorldAUSTIN, Texas, June 17...
PR Newswire
Positive Clinical Data on Biomarkers in Patients Receiving Reqorsa Gene Therapy Published at the 2026 ASCO Annual Meeting
Positive Clinical Data on Biomarkers in Patients Receiving Reqorsa Gene Therapy Published at the 2026 ASCO Annual Meeting Positive Clinical Data on Biomarkers in Patients Receiving Reqorsa Gene Therapy Published at the 2026 ASCO Annual Meeting PR Newswire AUSTIN, Texas, May 26, 2026 Trop-2 H-scores...
PR Newswire
Genprex Collaborators Present Positive Preclinical Data on Diabetes Gene Therapy for Type 2 Diabetes at the 2026 American Society of Gene and Cell Therapy Annual Meeting
Genprex Collaborators Present Positive Preclinical Data on Diabetes Gene Therapy for Type 2 Diabetes at the 2026 American Society of Gene and Cell Therapy Annual Meeting Genprex Collaborators Present...
PR Newswire
Genprex Receives Patent Grant from The Israel Patent Office for the Combination of Reqorsa Gene Therapy and PD-1 Antibodies to Treat Cancer
Genprex Receives Patent Grant from The Israel Patent Office for the Combination of Reqorsa Gene Therapy and PD-1 Antibodies to Treat Cancer Genprex Receives Patent Grant from The Israel Patent Office for the Combination of Reqorsa Gene Therapy and PD-1 Antibodies to Treat Cancer PR Newswire AUSTIN...
PR Newswire
Genprex Collaborators to Present Positive Preclinical Data on Diabetes Gene Therapy for Type 2 Diabetes at the 2026 American Society of Gene and Cell Therapy Annual Meeting
Genprex Collaborators to Present Positive Preclinical Data on Diabetes Gene Therapy for Type 2 Diabetes at the 2026 American Society of Gene and Cell Therapy Annual Meeting Genprex Collaborators to...
PR Newswire
Positive Clinical Data on Biomarkers in Patients Receiving Reqorsa Gene Therapy To Be Released at the 2026 ASCO Annual Meeting
Positive Clinical Data on Biomarkers in Patients Receiving Reqorsa Gene Therapy To Be Released at the 2026 ASCO Annual Meeting Positive Clinical Data on Biomarkers in Patients Receiving Reqorsa Gene...
PR Newswire
Genprex Signs Sponsored Research Agreement to Study Biomarkers that May Predict Patient Response to Reqorsa Gene Therapy
Genprex Signs Sponsored Research Agreement to Study Biomarkers that May Predict Patient Response to Reqorsa Gene Therapy Genprex Signs Sponsored Research Agreement to Study Biomarkers that May...
PR Newswire
Genprex Collaborators Present Positive Preclinical Data on the Use of Reqorsa Gene Therapy for the Treatment of Lung Cancer at the 2026 AACR Annual Meeting
Genprex Collaborators Present Positive Preclinical Data on the Use of Reqorsa Gene Therapy for the Treatment of Lung Cancer at the 2026 AACR Annual Meeting Genprex Collaborators Present Positive...
PR Newswire
Genprex Collaborators to Present Positive Preclinical Data on the Use of Reqorsa Gene Therapy for the Treatment of Lung Cancer at the 2026 AACR Annual Meeting
Genprex Collaborators to Present Positive Preclinical Data on the Use of Reqorsa Gene Therapy for the Treatment of Lung Cancer at the 2026 AACR Annual Meeting Genprex Collaborators to Present...
PR Newswire
<
1
2
...
>
Advertisement|Remove ads.
Latest GNPX News
ViewGenprex Receives a Notice of Allowance from The Canadian Intellectual Property Office for a Patent Claiming the Combination of Reqorsa Gene Therapy with Either PD-1 or PD-L1 Antibodies to Treat Cancer
PR Newswire
Genprex to Participate at BIO International Convention 2026
PR Newswire
Positive Clinical Data on Biomarkers in Patients Receiving Reqorsa Gene Therapy Published at the 2026 ASCO Annual Meeting
PR Newswire
Advertisement|Remove ads.